Pharmaceutical Technology and Biopharmaceutics, LMU Munich, Munich, Germany.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Sep;12(5):e1634. doi: 10.1002/wnan.1634. Epub 2020 Apr 8.
Despite the large number of drugs available for the treatment of asthma, in 5-10% of the patients this disease is not well controlled. While most treatments palliate symptoms, those suffering from severe and uncontrolled asthma could benefit more from a therapeutic approach addressing the root problem. An siRNA-based therapy targeting the transcription factor GATA3 in activated T helper cells subtype 2 (T 2 cells), one of the key upstream factors involved in asthma, could therefore represent a promising strategy. However, the difficult-to-transfect cell type has not extensively been explored for nucleic acid therapeutics. In this regard, our group first identified a suitable pathway, that is, transferrin receptor mediated uptake, to target efficiently and specifically activated T 2 cells with a transferrin-polyethyleneimine (PEI) conjugate which forms polyplexes with siRNA. This system, despite efficient uptake in activated T cells (ATCs) in vivo, suffered from poor endosomal release and was later improved by a combination with a melittin-PEI conjugate. The new formulation showed improved endosomal escape and gene silencing efficacy. Additionally, in order to develop a clinically relevant dosage form for pulmonary delivery of siRNA we have lately focused on a dry powder formulation by spray drying (SD) for the production of inhalable nano-in-microparticles. In proof-of-concept experiments, DNA/PEI polyplexes were used in order to implement analytics and engineer process parameters to pave the way for SD also siRNA containing polyplexes and more sophisticated systems in general. Ultimately, our efforts are devoted to the development of a novel treatment of asthma that can be translated from bench to bedside and are reviewed and discussed here in the context of the current literature. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Biology-Inspired Nanomaterials > Protein and Virus-Based Structures.
尽管有大量的药物可用于治疗哮喘,但仍有 5-10%的患者病情无法得到很好的控制。虽然大多数治疗方法都能缓解症状,但那些患有严重和无法控制的哮喘的患者可能会从针对根本问题的治疗方法中获益更多。一种基于 siRNA 的疗法针对转录因子 GATA3,GATA3 是参与哮喘的关键上游因素之一,在激活的 T 辅助细胞 2 型(T2 细胞)中靶向,因此可能是一种很有前途的策略。然而,对于核酸疗法,尚未广泛探索难以转染的细胞类型。在这方面,我们的研究小组首先确定了一种合适的途径,即转铁蛋白受体介导的摄取,用转铁蛋白-聚乙烯亚胺(PEI)缀合物靶向高效和特异性地激活 T2 细胞,该缀合物与 siRNA 形成多聚物。尽管该系统在体内能有效地被激活的 T 细胞(ATCs)摄取,但后来由于内体释放不良而受到限制,后来通过与蜂毒素-PEI 缀合物结合得到了改善。新配方显示出改善的内体逃逸和基因沉默效果。此外,为了开发用于肺部递送 siRNA 的临床相关剂型,我们最近专注于喷雾干燥(SD)生产可吸入纳米-微米粒子的干粉制剂。在概念验证实验中,使用 DNA/PEI 多聚物来实施分析和工程工艺参数,为 SD 以及包含多聚物和更复杂系统的 siRNA 铺平道路。最终,我们的努力致力于开发一种新型的哮喘治疗方法,可以从实验室转化到临床,并在当前文献的背景下进行了回顾和讨论。本文属于以下类别:治疗方法和药物发现 > 呼吸疾病的纳米医学 > 基于核酸的结构 生物启发型纳米材料 > 基于蛋白质和病毒的结构。